Table 1

Baseline clinical characteristics

Variable, n (%)Placebo (n=11)Drug (n=11)p Value*
Age, years64±12.564.5±11.20.97
Male gender9 (82)7 (64),0.34
BMI, kg/m231±6.530.4±5.10.95
DiagnosisUA=6 (55), NSTEMI=5 (45)UA=3 (27), NSTEMI=8 (73)0.19
History of MI2 (18.2)1 (9.1)0.53
Prior PCI2 (18.2)3 (27.3)0.61
Family history of CAD9 (81.8)5 (45.5)0.19
Current smoking3 (27.3)1 (9.1)0.44
Hyperlipidaemia10 (91)6 (54.6)0.058
Diabetes mellitus2 (18.2)3 (27.3)0.61
Hypertension9 (81.8)8 (72.7)0.61
Total cholesterol, mg/dL183±48.5177.8±41.20.79
TGs, mg/dL105 (88, 164)104 (61, 195)0.65
LDL cholesterol, mg/dL111±46102±430.63
HDL cholesterol, mg/dL45.5±9.444.7±130.87
Creatinine (mg/dL)1.0 (0.9, 1.1)1.1 (0.8, 1.2)0.59
Baseline medications
Aspirin7 (64)5 (45)0.39
Clopidogrel1 (9)3 (27)0.27
β-Blockers3 (27)6 (55)0.19
ACE inhibitors4 (36)3 (27)0.65
Statins4 (36)5 (45)0.67
CCBs2 (18)0 (0)0.14
Warfarin0 (0)1 (9)0.31
Digoxin0 (0)1 (9)0.31
Diuretics2 (18)2 (18)1.00
Oral hypoglycaemics2 (18)3 (27)0.61
  • *p Values for pretreatment comparisons are provided for descriptive purposes. Data are expressed as mean±SD, median (IQR) or number (percentage).

  • ACE, ACE inhibitors; BMI, body mass index; CAD, coronary artery disease; CCB, calcium channel blocker; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MI, myocardial infarction; NSTEMI, non-ST elevation myocardial infarction; PCI, percutaneous coronary intervention; TG, triglycerides; UA, unstable angina.